Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Atopic Dermatitis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.

Some of the key takeaways from the Atopic Dermatitis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years.

*
Atopic Dermatitis companies working in the treatment market are Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment

*
Emerging Atopic Dermatitis therapies in the different phases of clinical trials are- PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.

*
In March 2024, Sanofi has reported promising results from the second phase of a study involving the OX40 antibody amlitelimab, demonstrating sustained improvement in treating moderate to severe atopic dermatitis symptoms in patients who had previously received treatment.

Atopic Dermatitis Overview

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by red, itchy rashes. It is a type of dermatitis that tends to flare up periodically and often occurs in individuals with a personal or family history of allergic conditions like asthma, hay fever, or allergic rhinitis.

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:

*
PF 07242813: Pfizer

*
KT-474: Kymera Therapeutics

*
BEN2293: BenevolentAI

*
MEDI3506: AstraZeneca

*
Q301: Qurient

*
SB011: Sterna Biologicals

*
Tradipitant: Vanda Pharmaceuticals

*
Roflumilast: Arcutis Biotherapeutics

Atopic Dermatitis Route of Administration

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Atopic Dermatitis Molecule Type

Atopic Dermatitis Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Atopic Dermatitis Pipeline Therapeutics Assessment

*
Atopic Dermatitis Assessment by Product Type

*
Atopic Dermatitis By Stage and Product Type

*
Atopic Dermatitis Assessment by Route of Administration

*
Atopic Dermatitis By Stage and Route of Administration

*
Atopic Dermatitis Assessment by Molecule Type

*
Atopic Dermatitis by Stage and Molecule Type

DelveInsight's Atopic Dermatitis Report covers around 110+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Atopic Dermatitis Therapeutics Market include:

Key companies developing therapies for Atopic Dermatitis are - GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regenron Pharmaceutical Inc., Abbvie Inc., Allergan PLC, Bausch Health Companies Inc., Evelo Biosciences, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others.

Atopic Dermatitis Pipeline Analysis:

The Atopic Dermatitis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.

*
Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Atopic Dermatitis Pipeline Market Drivers

*
Rising prevalence of AD, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.

Atopic Dermatitis Pipeline Market Barriers

*
However, over-the-counter medications, outdated treatment recommendations - Poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.

Scope of Atopic Dermatitis Pipeline Drug Insight

*
Coverage: Global

*
Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others

*
Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others

*
Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies

*
Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Atopic Dermatitis Report Introduction

2. Atopic Dermatitis Executive Summary

3. Atopic Dermatitis Overview

4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment

5. Atopic Dermatitis Pipeline Therapeutics

6. Atopic Dermatitis Late Stage Products (Phase II/III)

7. Atopic Dermatitis Mid Stage Products (Phase II)

8. Atopic Dermatitis Early Stage Products (Phase I)

9. Atopic Dermatitis Preclinical Stage Products

10. Atopic Dermatitis Therapeutics Assessment

11. Atopic Dermatitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Atopic Dermatitis Key Companies

14. Atopic Dermatitis Key Products

15. Atopic Dermatitis Unmet Needs

16 . Atopic Dermatitis Market Drivers and Barriers

17. Atopic Dermatitis Future Perspectives and Conclusion

18. Atopic Dermatitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-pipeline-review-2024-clinical-trials-update-and-market-impact-by-delveinsight-glaxosmithkline-plc-nestle-sa-pfizer-inc-regeneron-pharma-abbvie-allergan-plc-bausch-health]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.